PhaseII trial of carbon-ion radiotherapy with DAVFeron for head and neck melanoma. (HIMAT1302)

PhaseII trial of carbon-ion radiotherapy with DAVFeron for head and neck melanoma. (HIMAT1302) - PhaseII trial of carbon-ion radiotherapy with DAVFeron for head and neck melanoma. (HIMAT1302)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012419

Enrollment

Registered

2013-12-01

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant melanoma of head and neck

Interventions

C-RT:64GyE/16fraction(GTV over 40cc), 57.6GyE/16fraction(GTV under 40cc). Chemotherapy:DAVFeron

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)malignant melanoma with pathological diagonosis of head and neck. 2)hepatic, cardiac, and renal function are in tolerance level. 3)Performance status:0-2 4)the patient with over 6months prognosis 5)other

Exclusion criteria

Exclusion criteria: 1)with history of radiotherapy 2)with another active cancer 3)with active infection 4)with metal material could not be removed 5)other

Design outcomes

Primary

Measure	Time frame
3year overall and cause-specific survival rate	—

Secondary

Measure	Time frame
loral control rate normal tissue reaction	—

Countries

Japan

Contacts

Public ContactHiroaki Suefuji

Ion Beam Therapy Center, SAGA HIMAT Foundation radiology

sufg@saga-himat.jp0942-81-1897

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026